Medical Oncologist
Janson Trieu, MD
Janson Trieu, MD is part of Comprehensive Cancer’s board certified and award-winning medical oncologist team that provides world-class cancer care in a supportive and caring environment.
EDUCATION
Dr. Trieu attended Johns Hopkins University in Baltimore, Maryland for his undergraduate studies. He graduated with a Bachelor of Science in molecular and cellular biology. He received his medical degree from the University of Arizona College of Medicine – Tucson in 2018. Dr. Trieu then went on to complete his residency in internal medicine at the University of Nevada, Las Vegas and his fellowship in hematology and medical oncology at the Levine Cancer Institute in Charlotte, North Carolina.
EXPERIENCE
Dr. Trieu is a medical oncologist and hematologist at Comprehensive Cancer Centers where he treats patients at the Central Valley treatment center. Prior to joining Comprehensive Cancer Centers in 2024, Dr. Trieu co-founded the Hematology and Oncology Interest Group at UNLV, which focuses on connecting residents with faculty for research and mentorship. He has also contributed to a number of medical journals.
PERSONAL
Dr. Trieu loves spending time with friends and family in beautiful Las Vegas. Outside of work, he enjoys visiting art museums, trying out new restaurants, and watching Vegas performances. He can also be spotted attending music concerts and art festivals. Whenever possible, he likes to travel abroad to Asia. He keeps physically active by taking hip hop dance classes.
PATIENT PHILOSOPHY
A new cancer diagnosis is absolutely life altering for patients and their families. My goal is to help my patients understand their diagnosis by providing clear information that is easily digestible. I am a firm believer in striving for a balance between cancer therapy and quality of life. Treatments for cancer have changed dramatically over time and there are exciting new innovations year after year. I wish to provide compassionate, up to date care for my patients in a welcoming, local environment.
BOARD CERTIFIED
Internal Medicine, American Board of Internal Medicine
BOARD ELIGIBLE
Medical Oncology, American Board of Internal Medicine
Hematology, American Board of Internal Medicine
MEMBERSHIPS IN PROFESSIONAL ASSOCIATIONS
American Board of Internal Medicine
American Society of Clinical Oncology
American Society of Hematology
TREATMENT CENTER
Comprehensive Central Valley – Twain
- PUBLICATIONS
Trieu J, Chang M, Rojas V, et al. Lower Fracture Rates in Patients Treated with Radium-223, Abiraterone or Enzalutamide, When Given Concurrently with Bone Health Agents: A Real-World Analysis. Clin Genitourin Cancer. 2022;20(5):399-403. doi: 10.1016/J.CLGC.2022.04.015 - Shohdy KS, Villamar DM, Cao Y, et al. Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. Br J Cancer. 2022;126(3). do:10.1038/S41416-021-01648-8
- Cao Y, Trieu J, Elias M, et al. Osteonecrosis of the jaw (ONJ) in radium 223 (Ra223)-treated metastatic castration-resistant prostate cancer (mCRC) patients (pts) with exposure to zoledronic acid and/or denosumab 2020 ASCO Annual Meeting, accepted for Poster Session
- Cao YTKH, Elias M, Trieu J, Rojas V, Anderson MJ, Vogelzang NJ. Fracture rates in radium223 (Ra223) treated mCRPC patients (pts): Areal-world analysis in 177 pts treated at a single community center 2010-2018. https://doi.org/101200/JCO2020386_suppl41. 2020;38(6_suppl):41-41.doi:10.1200/JCO.2020.38.6_SUPPL.41
- Hayman J, Phillips R, Chen D, et al. Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality. Prostate. 2018:78(8):623-630. do:10.1002/PROS.23507
- Peng LC. , Narang AK, Gergis C, et al. Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy. Urol Oncol. 2018;36(6):309.7-309.14. do:10.1016/J.UROLONC.2018.02.008
- Narang AK, Trieu J, Radwan N, et al. End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2017;20(2):203. do:10.1038/PCAN.2016.67
- Soong RS, Song L, Trieu J, et al. Direct T cell activation via CD4o ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors. PLoS One. 2014;9(3). doi: 10.1371/JOURNAL.PONE.0093162
- Soong RS, Song L, Trieu J, et al. Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNy. Clin Cancer Res. 2014;20(21):5456-5467. do: 10.1158/1078-0432.CCR-14-0344
- Soong RS, Trieu J, Lee SY, et al. Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53. PLoS One. 2013;8(2). do: 10.1371/JOURNAL.PONE.0056912
This form is not intended for current patients of Comprehensive. If you are a patient, please contact your treatment center with any questions.
If you are experiencing a medical emergency, please call 911 immediately or go to the nearest emergency room. This form is not intended for emergencies.